Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Key Highlights
- ➤Myriad’s Precise MRD detected colorectal cancer recurrence before clinical recurrence, with four-month median lead time
- ➤More than half of postsurgical colorectal ctDNA-positive patients had ultra-sensitive levels below 100 parts per million
- ➤Pancreatic cancer patients with postsurgical MRD had significantly worse recurrence-free survival
- ➤Personalized panels succeeded for all evaluable pancreatic cancer patients; half reached 1,000 variants
Expert Statements
Dale Muzzey, Chief Scientific Officer, Myriad Genetics
“These data reinforce the potential of Precise MRD to bring more sensitive, personalized monitoring to cancers where recurrence can be difficult to identify until disease burden is higher.”
Dale Muzzey, Chief Scientific Officer, Myriad Genetics
“By leveraging whole-genome sequencing to build individualized panels capable of detecting ctDNA at very low levels, Precise MRD may help clinicians identify recurrence risk earlier and make more informed decisions about patient management following surgery.”
Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East and principal investigator of the MONSTAR-SCREEN-3 study
“Together, these findings add to a growing body of evidence supporting ultra-sensitive MRD detection as a tool to improve post-surgical risk stratification and disease monitoring.”
Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East and principal investigator of the MONSTAR-SCREEN-3 study
“The consistent association between post-operative ctDNA detection and patient outcomes, coupled with the ability to identify recurrence months before conventional methods, highlights the potential clinical value of ultra-sensitive MRD assessment for guiding follow-up strategies in patients with resectable cancers.”
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing (WGS)-based Precise MRD™ platform to support ultra-sensitive molecular residual disease (MRD) detection in patients with resectable colorectal and pancreatic cancers.
The findings, which will be presented as part of the European Society for Medical Oncology (ESMO) Congress 2026, reinforce the role of highly sensitive MRD testing after curative-intent surgery in tumor types where earlier insight into recurrence risk may help inform monitoring and treatment decisions.
Get started
Create a free account to read the full story.